ASND vs. ROIV: Ascendis Pharma vs. Roivant Sciences Stock Comparison
How do Ascendis Pharma (ASND) and Roivant Sciences (ROIV) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Ascendis Pharma (ASND) and Roivant Sciences (ROIV) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | ASND | ROIV |
|---|---|---|
| Name | Ascendis Pharma A/S | Roivant Sciences Ltd. |
| Country/Region | Denmark | United Kingdom |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 16.90 billion USD | 28.08 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | January 28, 2015 | December 8, 2020 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ASND | ROIV |
|---|---|---|
| Total Return (1Y) | 29.46% | 96.75% |
| Total Return (3Y, Annualized) | 40.62% | 68.04% |
| Total Return (5Y, Annualized) | 10.03% | 36.73% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ASND | ROIV |
|---|---|---|
| Volatility (1Y, Annualized) | 38.62% | 47.99% |
| Beta (5Y) | 0.38 | 1.17 |
| Max Drawdown (5Y) | -55.93% | -79.22% |
| Avg. Volume (3M) | 698.39K | 7.82M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ASND | ROIV |
|---|---|---|
| Sharpe Ratio (1Y) | 0.65 | 1.93 |
| Sortino Ratio (1Y) | 0.99 | 4.03 |
Profitability
ROE (TTM)
Roivant Sciences (ROIV) reports a negative ROE of -8.52%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Ascendis Pharma (ASND) reports 118.78%, ranking against industry peers normally.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
118.78%
- ASND
- 118.78%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
-8.52%
- Max
- 109.18%
- Q3
- 6.23%
- ROIV
- -8.52%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Ascendis Pharma (ASND) at 70.85% converts revenue to bottom-line profit above its industry’s benchmark range, while Roivant Sciences (ROIV) at 0.00% keeps roughly the typical share for its industry.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
70.85%
- ASND
- 70.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- ROIV
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Roivant Sciences (ROIV) reports a negative operating margin of -25,408.11%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Ascendis Pharma (ASND) reports 64.98%, ranking against industry peers normally.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
64.98%
- Max
- 83.12%
- ASND
- 64.98%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
-25,408.11%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
- ROIV
- -25,408.11%
Profitability Metrics
| Metric | ASND | ROIV |
|---|---|---|
| ROE (TTM) | 118.78% | -8.52% |
| ROA (TTM) | 9.58% | -16.28% |
| Net Margin (TTM) | 70.85% | 0.00% |
| Operating Margin (TTM) | 64.98% | -25,408.11% |
| Gross Margin (TTM) | 91.30% | 0.00% |
Growth
Revenue Growth
Ascendis Pharma (ASND) at 98.03% sits in the top revenue growth quartile, while Roivant Sciences (ROIV) at -71.57% is in the bottom quartile, showing a clear gap in revenue momentum.
EPS Growth
Neither Ascendis Pharma (ASND) nor Roivant Sciences (ROIV) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | ASND | ROIV |
|---|---|---|
| Revenue Growth (YoY) | 98.03% | -71.57% |
| Revenue Growth (3Y CAGR) | 141.43% | -36.01% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Ascendis Pharma (ASND) at 2.99 keeps current ratio within its industry’s typical mid-range, while Roivant Sciences (ROIV) at 16.72 sits above its industry’s typical mid-range — comfortable liquidity, though possibly with more idle current assets relative to peers.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.99
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ASND
- 2.99
- Q1
- 2.47
- Min
- 0.10
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.72
- Max
- 25.13
- ROIV
- 16.72
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Ascendis Pharma (ASND) at 0.31 and Roivant Sciences (ROIV) at 0.02 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.31
- Max
- 1.42
- Q3
- 0.65
- ASND
- 0.31
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.02
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- ROIV
- 0.02
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ASND | ROIV |
|---|---|---|
| Current Ratio (MRQ) | 2.99 | 16.72 |
| Debt / Equity (MRQ) | 0.31 | 0.02 |
| Net Debt / EBITDA | -1.37 | -- |
Dividends
Dividend Yield (TTM)
Neither Ascendis Pharma (ASND) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ASND
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ROIV
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Ascendis Pharma (ASND) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ASND
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ROIV
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ASND | ROIV |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Ascendis Pharma (ASND) trades at 19.68 times trailing earnings, ranked against its peers, while Roivant Sciences (ROIV) has no P/E ratio this period.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.68
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- ASND
- 19.68
- Q1
- 13.30
- Min
- 0.07
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- ROIV
- --
P/S Ratio (TTM)
Ascendis Pharma (ASND) at 16.14 prices around its industry’s typical P/S ratio, while Roivant Sciences (ROIV) at 3,728.61 clears its benchmark range — ROIV looks notably rich on sales.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.14
- Max
- 58.18
- Q3
- 25.77
- ASND
- 16.14
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
3,728.61
- ROIV
- 3,728.61
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Both Ascendis Pharma (ASND) at 10.45 and Roivant Sciences (ROIV) at 6.64 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.45
- Max
- 13.53
- ASND
- 10.45
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.64
- Max
- 13.53
- ROIV
- 6.64
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ASND | ROIV |
|---|---|---|
| P/E Ratio (TTM) | 19.68 | -- |
| P/S Ratio (TTM) | 16.14 | 3,728.61 |
| P/B Ratio (MRQ) | 10.45 | 6.64 |
| Free Cash Flow Yield (TTM) | 0.08% | -3.98% |